Aurinia Pharmaceuticals Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated November 13, 2015, serves as a report of a foreign private issuer filed by Aurinia Pharmaceuticals Inc. The filing acts as a cover document to furnish the U.S. Securities and Exchange Commission with interim financial information for the third quarter ended September 30, 2015.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached exhibits, specifically Exhibit 99.1 (Interim Condensed Consolidated Financial Statements) and Exhibit 99.2 (Management's Discussion and Analysis), which are referenced but not included in the source text.
Material Changes
The source text does not provide data to compare current period performance against prior periods. No material changes are described in the cover document itself.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, risk factors, or details on contingencies. Such information is expected to be found in the referenced MD&A (Exhibit 99.2).
Investor Verification Checklist
- Review Exhibit 99.1 for the specific interim condensed consolidated financial statements for the quarter ended September 30, 2015.
- Examine Exhibit 99.2 for the Management's Discussion and Analysis to understand operational performance and financial trends.
- Verify the certifications provided by the Chief Executive Officer (Exhibit 99.3) and Chief Financial Officer (Exhibit 99.4).
- Confirm that the filing is submitted pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.